University of Michigan Rogel Cancer Center

09/02/2026

Ready to make your miles matter? 👟✨ Sign up for the 2nd Annual Michigan Cancer Challenge 5K benefitting the University of Michigan Health Rogel Cancer Center!

On Saturday, October 10 at 10:00 a.m., we’re joining our hosts, the Shenandoah Young Adult Committee, at the Shenandoah Country Club for a morning filled with fitness, community, and purpose.

What you can look forward to:
🏃‍♂️ A well-organized, scenic 5K course
🍎 Post-run refreshments to refuel
🎉 A welcoming, high-energy atmosphere for individuals, families, and groups
🔬 The chance to advance life-saving cancer research

Every single registration helps fund the Shenandoah Young Adult Committee x Michigan Medicine 5K Fund, supporting patient programs and areas of greatest need at the Rogel Cancer Center. Spaces will fill up, so don’t wait!
https://michiganmedicine.donordrive.com/events/851

08/28/2026

SPECIALIZED CARE FOR RARE LIPOSARCOMA DIAGNOSIS: Virginia Fallis, age 64, never expected a routine checkup to change her life. During a regularly scheduled visit with her primary care physician in 2024, an EKG revealed an unexpected abnormality around her left ventricle.

Additional imaging revealed a cancerous tumor. Within days, Fallis learned that she had well-differentiated liposarcoma. Following her diagnosis, her care team quickly developed a surgical plan. The tumor, which weighed nearly four pounds, was wrapped around organs inside her chest, making the operation especially complex.

Today, Fallis' care involves a multidisciplinary team of oncologists, physician assistants, nurses, pharmacists and other specialists who coordinate her treatment, answer questions and help navigate everything from medications to insurance approvals.

Learn more about her story: https://michmed.org/jjjb5

08/21/2026

About one in eight men are diagnosed with prostate cancer during their lifetime. Although many survive, it can develop into metastatic disease.

Certain drugs are initially effective, but nearly all patients eventually become resistant to treatment. Through a process called transdifferentiation, resistant tumors adapt by activating different pathways that allow them to take on different identities.

In a new study U-M researchers identified two pathways that can simultaneously be targeted to treat transdifferentiated prostate tumors.

Learn more about the study: https://michmed.org/nMVew.

08/13/2026

📞 nurses, physicians, physicians in training, medical students, nurse
practitioners, and other Healthcare professionals, Join us at the Updates in Breast Cancer Symposium, Sept. 19, 2026 Info and registration: https://michmed.org/PPnX9

07/25/2026

We’re thrilled to announce the 2nd Annual Michigan Cancer Challenge 5K, hosted by the Shenandoah Young Adult Committee to benefit the University of Michigan Health Rogel Cancer Center! 💙💛

Get ready to run, walk, and make a difference at the beautiful Shenandoah Country Club in West Bloomfield on Saturday, October 10 at 10:00 a.m. Net proceeds will directly support patient programs and life-saving research at Rogel Cancer Center.

Whether you’re aiming for a personal best or just want a fun morning of fitness, this is your official invitation. Tag your running buddy, rally your coworkers, or sign up the whole family!

Register here: https://www.michigancancerchallenge.org

07/14/2026

We’re thrilled to announce the 2nd Annual Michigan Cancer Challenge 5K, hosted by the Shenandoah Young Adult Committee to benefit the University of Michigan Health Rogel Cancer Center! 💙💛

Get ready to run, walk, and make a difference at the beautiful Shenandoah Country Club in West Bloomfield on Saturday, October 10 at 10:00 a.m. Net proceeds will directly support patient programs and life-saving research at Rogel Cancer Center.

Whether you’re aiming for a personal best or just want a fun morning of fitness, this is your official invitation. Tag your running buddy, rally your coworkers, or sign up the whole family!

Register here: michigancancerchallenge.org

07/13/2026

A promising step forward in pancreatic cancer research. Learn how daraxonrasib, one of the first major breakthroughs in pancreatic cancer treatment in years, could help reshape the future of care. Hear from Dr. Costas Lyssiotis, a researcher at the Rogel Cancer Center, about what this discovery means for patients and ongoing research.

07/09/2026

In the U.S. about half of prostate cancer cases in patients of European ancestry is due to the protein ERG, which increases the growth and migration of tumor cells.

ERG has been considered undruggable because it lacks the usual pockets that a drug can bind to. U-M researchers have developed a small molecule called PBITE-1 that can bind to ERG, disrupting its ability to drive the development of prostate cancer.

Learn more by following the link in comments.

06/30/2026

While brain cancers are not always lethal, the most common form, glioblastoma, is aggressive and incurable, with a median survival of one and a half years.

From identifying deadly tumors sooner, understanding the biology of how and why they grow, and uncovering promising new treatments, U-M researchers are carving a path that creates hope for patients.

Learn about the latest research at https://michmed.org/KdrXX.

For patients facing brain cancer, every moment matters. At the Roge...

05/14/2026

COORDINATED CARE FROM DIFFERENT SPECIALITIES FOR BREAST CANCER TREATMENT: Sara Cederberg, 41, was getting ready to go to bed one night and noticed an abnormality in her breast. She immediately contacted her primary care physician and asked for a referral to the University of Michigan Health Rogel Cancer Center.

“I believed it was important to come to the University of Michigan because I wanted to work with a team that had knowledge on recent developments in cancer care and access to clinical trials,” Cederberg said.

After a few tests, including a mammogram, ultrasound and biopsy, Cederberg’s care team confirmed that she had estrogen-positive breast cancer. According to the initial imaging, the tumor was smaller than a walnut and she also had abnormal lymph nodes.

Her care team offered Cederberg a clinical trial that included specialized testing of her tumor. Although the results indicated that she was not eligible for experimental treatment, she needed both chemotherapy and surgery.

Her team allowed her to choose which treatment to begin first, and she chose to proceed with chemotherapy in May 2025 and underwent surgery in October 2025.

“Her situation was notable because it involved coordination between pathology, radiology, surgery, oncology and the clinical research team” said Anne Schott, M.D., Clinical Professor of Internal Medicine-Hematology/Oncology. “We quickly came together to develop a treatment plan and ensure that Sara’s care was transferred smoothly among different divisions.”

After surgery, Cederberg also underwent radiation treatment and is currently on endocrine therapy.

“Like anyone else who has a cancer diagnosis, I thought my journey would be difficult. Although many people go through a hard time, I was able to continue working, stay active and go on a few trips during chemotherapy and radiation,” she said. “Everyone at Rogel tried to make me feel comfortable and offered me support.”

Cederberg now spends her time traveling, going to concerts, working out, bird watching and hiking.